Advertisement

InflammoPharmacology

, Volume 11, Issue 4–6, pp 471–562 | Cite as

Programme and Abstracts

Article
  • 66 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. Buchanan, W. W. and Kean, W. F. (2002a). OsteoarthritisI: Epidemiological risk factors and historical considerations, Inflammopharmacology 10, 5–21.Google Scholar
  2. Buchanan, W. W. and Kean, W. F. (2002b). Osteoarthritis II: Pathology and pathogenesis, Inflammopharmacology 10, 23–52.Google Scholar
  3. Buchanan, W. W. and Kean, W. F. (2002c). Osteoarthritis III: Radiological and clinical definition, Inflammopharmacology 10, 53–78.Google Scholar
  4. Buchanan, W. W. and Kean, W. F. (2002d). Osteoarthritis IV: Clinical therapeutic trials and treatment, Inflammopharmacology 10, 79–155.Google Scholar
  5. Forrest, J. B. (1992). Sympathetic mechanisms in post operative pain. Can. J. Anaesth. 39, 523–527.PubMedGoogle Scholar

REFERENCES

  1. Crotti, T. N., et al. (2003). Receptor activator NFκβ ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis, J. Periodont. Res. (in press).Google Scholar
  2. Haynes, D. R., et al. (2001a). Osteoprotergerin and receptor activator of nuclear factor kappab ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint, Rheumatology 40, 623–630.PubMedGoogle Scholar
  3. Haynes, D. R., et al. (2001b). The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis, J. Bone Joint Surg. 83B, 902–911.Google Scholar
  4. Kong, Y.-Y., et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature 397, 315–323.PubMedGoogle Scholar
  5. Lacey, D. L., et al. (1998). Osteoprotegerinligand is a cytokine that regulates osteoclast differentiation and activation, Cell 93, 165–176.PubMedGoogle Scholar
  6. Yasuda, H., et al. (1998). Osteoclast differentiationfactor is a ligand for osteoprotegerin/ osteoclast in-hibitory factor and is identical to TRANCE / RANKL, Proc. Natl. Acad. Sci. USA 95, 3597–3602.PubMedGoogle Scholar

REFERENCES

  1. Cheras, P. A., et al. (1993). Osteoarthr. Cartil. 1, 219.PubMedGoogle Scholar
  2. Cheras, P. A., et al. (1997). Clin. Orthoped. 334, 57.Google Scholar
  3. Cheras, P. A. (1997). In: Osteonecrosis: Etiology, Diagnosis and Treatment, Urbaniak, J. R. and Jones, J. P. (Eds). American Academy of Orthopaedic Surgeons, Rosemont IL.Google Scholar
  4. Ghosh, P. and Cheras, P. A. (2001). Best Pract. Res. Clin. Rheumatol. 15, 693.PubMedGoogle Scholar

REFERENCES

  1. Tallon, D., Chard, J. and Dieppe, P. (2000). Lancet 13, 312–319.Google Scholar

REFERENCES

  1. Bartleson, J. D. (2002). Pain Man 3, 2620.Google Scholar
  2. Bender, T., et al. (2001). Arzneim. Forsch./ Drug Res. 51, 489.Google Scholar
  3. Heyneman, C. A., et al. (2002). Drugs 60, 555.Google Scholar
  4. Jeal, W. and Banfield, P. (1997). Drugs 53, 109.PubMedGoogle Scholar
  5. More, R. A., et al. (1998). Br. Med. J. 316, 333.Google Scholar
  6. Paolino, D., et al. (2002). Int. J. Pharm. 244, 21.PubMedGoogle Scholar
  7. Rosenstein, E. D. (1999). Rheumatol. DS Clin. N. Am. 25, 899.Google Scholar
  8. Vaile, J. H. and Davis, P. (1998). Drugs 56, 783.PubMedGoogle Scholar

REFERENCES

  1. Vane, J. R. (1971). Nature 231, 232–239.Google Scholar
  2. Masferrer, J. L., Zweifel, B. S., et al. (1994). Proc. Natl. Acad. Sci. USA 91, 3228–3234.PubMedGoogle Scholar
  3. Pairet, M. and Van Ryn, J. (1999). Drugs Today 35, 251–265.Google Scholar
  4. Dequeker, J., Hawkey, C., et al. (1998). Br. J. Rheumatol. 37, 946–951.PubMedGoogle Scholar
  5. Hawkey, C., Kahan, A., et al. (1998). Br. J. Rheumatol. 37, 937–945.PubMedGoogle Scholar
  6. Degner, F. and Richardson, B. (2001). Inflammopharmacology 9, 71–80.Google Scholar
  7. Gagnier, A., et al. (2002). Ann. Rheum. Dis. 61, 290.PubMedGoogle Scholar

REFERENCES

  1. Dionne, R. A. and McCullagh, L. (1998). Clin. Pharmacol. Ther. 63, 694–701.PubMedGoogle Scholar
  2. Evans, A. M. (1996). J. Clin. Pharmacol. 36, S7–S15.Google Scholar
  3. Leising, G. (1996) J. Clin. Pharmacol. 36, 3S–6S.PubMedGoogle Scholar
  4. Rainsford, K. D. (1999). In: Ibuprofen, A Critical Bibliographic Review, Rainsford, K. D. (Ed.). Taylor & Francis, London.Google Scholar

REFERENCES

  1. Homandberg, G. A., et al. (1998). Osteoarthr. Cartil. 6, 231–244.PubMedGoogle Scholar
  2. Kominski, G. F., et al. (2002). Pub. Health Rep. 117, 185–189.Google Scholar
  3. Lachance L., et al. (2002). Osteoarthr. Cartil. 10, 849–854.PubMedGoogle Scholar
  4. Nuki, G. (2002). Rheum. Dis. Top. Rev. 9, 1–11.Google Scholar
  5. Petersson, I. F., et al. (1997). Ann. Rheum. Dis. 56, 64–67.PubMedGoogle Scholar
  6. Sowers, M., et al. (2002). Osteoarthr. Cartil. 10, 595–601.PubMedGoogle Scholar

REFERENCES

  1. Armstrong, S. and Lees, P. (1999). Am. J. Vet. Res. 60, 98–104.PubMedGoogle Scholar
  2. Landoni, M. F., et al. (1997). J. Vet. Pharmacol. Ther. 20, 1–16.Google Scholar
  3. Lees, P., et al. (1999). Cont. Profess. Dev. 2, 18–25.Google Scholar
  4. Lipscomb, V. J., et al. (2002). Vet. Rec. 150, 684–689.PubMedGoogle Scholar
  5. Millis, D. L., et al. (2002). Vet. Ther. 3, 453–464.PubMedGoogle Scholar
  6. Pelletier, J.-P., et al. (2000). J. Rheum. 27, 2893–2902.PubMedGoogle Scholar
  7. Toutain, P. L., et al. (2001). J. Vet. Pharmacol. Ther. 24, 43–55.PubMedGoogle Scholar

REFERENCES

  1. Boughton-Smith, N. K., et al. (2002). Arthritis and Rheum. 46, S134.Google Scholar
  2. Tinker, J., et al. (2003). J. Med. Chem. 46, 913.PubMedGoogle Scholar

REFERENCES

  1. Evans, S. M. and Whittle, B. J. R. (2001). Eur. J. Pharmacol. 429, 287–296.PubMedGoogle Scholar
  2. Evans, S. M. and Whittle, B. J. R. (2003). Eur. J. Pharmacol. 461, 63–71.PubMedGoogle Scholar
  3. Kiss, J., et al. (2001). Eur. J. Pharmacol. 420, 175–179.PubMedGoogle Scholar
  4. Lamarque, D., et al. (2000). Br. J. Pharmacol. 130, 1531–1538.PubMedGoogle Scholar
  5. Moilanen, E., Whittle, B. J. R. and Moncada, S. (1999). In: Inflammation: Basic Principles and Clinical Correlates, Gain, J. I. and Snyderman, R. (Eds), pp. 787–800. Lippincott, Williams & Wilkins, Philadelphia, PA.Google Scholar
  6. Wallace, J. L., et al. (1994). Eur. J. Pharmacol. 257, 249–255.PubMedGoogle Scholar

REFERENCES

  1. Peterson, L. (2000). Clin. Orthoped. 374, 212–234.Google Scholar
  2. Roosendaal, G., et al. (1997). J. Rheumatol. 24, 1350–1354.PubMedGoogle Scholar
  3. Roosendaal, G., et al. (1999). Arthritis Rheum. 42, 1025–1032.PubMedGoogle Scholar

REFERENCES

  1. Butters, D. E. and Whitehouse, M. W. (2003). Treating inflammation, some needless difficulties for gaining acceptance of effective natural products and traditional medicines, Inflammopharmacology 11, 97–110.PubMedGoogle Scholar
  2. Whitehouse, M. W., Butters, D. E., et al. (2001). NSAID gastropathy: prevention by celery seed extracts in disease-stressed rats, Inflammopharmacology 9, 201–209.Google Scholar

REFERENCES

  1. Burstein, S. H. (2000). Curr. Pharm. Res. 6, 1339–1345.Google Scholar
  2. Denko, C. W. (1985). In: Handbook of Inflammation, Bonta, I. L., et al. (Eds). Elsevier Science, Amsterdam.Google Scholar
  3. Malfait, A. M., et al. (2000). Proc. Natl. Acad. Sci. USA 97, 9561–9566.PubMedGoogle Scholar
  4. Villiger, A., et al. (1993). Arthritis Rheum. 36, S124.Google Scholar
  5. Walker, J., et al. (1997). Clin. Exp. Physiol. Pharmacol. 6, 291–299.Google Scholar

REFERENCES

  1. Rashad, S., et al. (1989). Lancet 2, 519.PubMedGoogle Scholar
  2. Rashad, S., et al. (1992). In: Rheumatology, State of the Art, Bálint, G., Gönör, B. and Hodinka, L. (Eds), p. 184. Excerpta Medica, Amsterdam.Google Scholar
  3. Rainsford, K. D., et al. (1972). In: Rheumatology, State of the Art, Bálint, G., Gönör, B. and Hodinka, L. (Eds), p. 177. Excerpta Medica, Amsterdam.Google Scholar
  4. Rainsford, K. D., et al. (1997). J. Pharm. Pharmacol. 49, 991.Google Scholar
  5. Rainsford, K. D., et al. (2003). Inflammopharmacology 10, 185–239.Google Scholar

REFERENCES

  1. Charles, P. C., Weber, K. S., et al. (1999). J. Neuroimmunol. 100, 64–73.PubMedGoogle Scholar
  2. De Groot, C. J. and Woodroofe, M. N. (2001). Progr. Brain Res. 132, 533–544.Google Scholar
  3. Mahad, D. J., Howell, S., et al. (2002). J. Neurol. Neurosurg. Psychiatr. 72, 498–502.PubMedGoogle Scholar
  4. Mahad, D. J., Lawry, J., et al. (2003). Mult. Scler. (in press).Google Scholar
  5. Simpson, J. E., Newcombe, J., et al. (2000a). Neuropathol. Appl. Neurobiol., 133–142.Google Scholar
  6. Simpson, J., Rezaie, P., et al. (2000b). J. Neuroimmunol. 108, 92–200.PubMedGoogle Scholar

REFERENCES

  1. Boutaud, O., et al. (2002). Proc. Natl. Acad. Sci. USA 99, 7130.PubMedGoogle Scholar
  2. Campos, C., et al. (1999). Eur. J. Pharmacol. 378, 339.PubMedGoogle Scholar
  3. Chandrasekharan, N. V., et al. (2002). Proc. Natl. Acad. Sci. USA 99, 13926.PubMedGoogle Scholar
  4. Graham, G. G., et al. (2001). Inflammopharmacology 9, 131.Google Scholar

REFERENCES

  1. Bathon, J. M., et al. (1992). J. Pharmacol. Exp. Ther. 260, 384–390.PubMedGoogle Scholar
  2. Burch, R. M. and DeHaas, C. (1990). Naunyn-Schmiedenb. Arch. Pharmacol. 342, 189–193.Google Scholar
  3. Ljunggren, O. and Lerner, U. H. (1990). Br. J. Pharmacol. 101, 382–386.PubMedGoogle Scholar
  4. Sharma (1991). Eur. J. Rheumatol. Inflamm. 11, 30–36.PubMedGoogle Scholar
  5. Sharma J. N. and Buchanan, W. W. (1994). Exp. Toxicol. Pathol. 46, 421–433.PubMedGoogle Scholar
  6. Sharma, J. N. and Wirth, K. (1996). Gen. Pharmacol. 27, 133–136.PubMedGoogle Scholar
  7. Sharma, J. N., et al. (1998). Inflammopharmacology 6, 9–17.Google Scholar
  8. Sharma, J. N., et al. (2000). Inflammopharmacology 8, 219–241.Google Scholar

REFERENCES

  1. Garavito, R. M. (2001). In: Handbook of Metalloproteins, Wieghardt, K., et al. (Eds). Wiley, Chichester.Google Scholar
  2. Heiden, W., Moeckel, G., et al. (1993). J. Comput.-Aid. Mol. Design 7, 503.Google Scholar
  3. Kurumbail, R. G., Stevens, I. S., et al. (1996). Nature 384, 644.PubMedGoogle Scholar
  4. Trummlitz, G. and Wittneben, H. (2001). Ann. Rheum. Dis. 60, Abs Sat 0080.Google Scholar
  5. Trummlitz, G. and Van Ryn, J. (2002). Curr. Opin. Drug. Discov. Dev. 5, 552.Google Scholar
  6. Van Ryn, J., Trummlitz, G., et al. (2001). Curr. Med. Chem. 7, 1145.Google Scholar

REFERENCES

  1. Allen, H. L., Wase, A., et al. (1980). Acta Orthoped. Scand. 51, 595–600.Google Scholar
  2. Paulson, S. K., Zhang, J. Y., et al. (2000). Drug Metab. Dispos. 28, 514–521.PubMedGoogle Scholar
  3. Rø, J., Sudmann, E., et al. (1976). Acta Orthoped. Scand. 47, 588–599.Google Scholar
  4. Simon, A. M., Manigrasso, M. B., et al. (2002). J. Bone Miner. Res. 17, 963–976.PubMedGoogle Scholar

REFERENCES

  1. D'Amour, F. E. and Smith, D. L. (1941). J. Pharm. Exp. Ther. 72, 74–78.Google Scholar
  2. Gronbech, J. E. and Lacy, E. R. (1995). Am. J. Physiol. 269:G737–G744.PubMedGoogle Scholar
  3. Gyires, K. and Rónai, A. Z. (2001). J. Pharm. Exp. Ther., 297, 1010–1015.Google Scholar
  4. Gyires, K., Rónai, A. Z., Tóth, G., et al. (1997) Life Sci., 60, 1337–1347.PubMedGoogle Scholar
  5. Gyires, K., Rónai, A. Z., Müllner, K., et al. (2000). Neuropharmacology 39, 961–968.PubMedGoogle Scholar
  6. Kurata, J. H., Honda, G. D. and Frankl, H. (1985). Am. J. Publ. Health 75, 625–629.Google Scholar
  7. Miyake, H., Inaba, N., Kato, S., et al. (1996). Dig. Dis. Sci. 41, 339–345.PubMedGoogle Scholar
  8. Whittle, B. J. R., Lopes-Bermonte, J. and Moncada, S. (1990). Br. J. Pharmacol. 99, 607–611.PubMedGoogle Scholar

REFERENCES

  1. Hunt, J. N. (1979). A procedure for measuring of gastric bleeding caused by drugs, Dig. Dis. Sci. 24, 525–528.PubMedGoogle Scholar
  2. Johns, R. A. (1999). Etodolac: An overview of a selective COX-2 inhibitor, Inflammopharmacology 7, 269–275.Google Scholar
  3. Morón, F., Mózsik, Gy., Nagy, L., et al. (1984). Evidence for the existence of gastric cytoprotective effects of atropine and cimetidine in humans, Acta Phys. Hung. 64, 181–186.Google Scholar
  4. Mózsik, Gy., Sarlós P., R ácz, I., et al. (2003). Evidence for the direct gastric protective effect of capsaicin in human healthy subject, Gastroenterology (in press).Google Scholar

REFERENCES

  1. Whitehouse, M. W., et al. (2001). Inflammopharmacology 9, 201–209.Google Scholar
  2. Rainsford, K. D., et al. (2003). J. Pharm. Pharmacol. 55 (in press).Google Scholar

REFERENCES

  1. Cooper, S. A. (1983). Am. J. Med. 75, 24–29.Google Scholar
  2. Dionne, R. A. and McCullagh, L. (1998). Clin. Pharmacol. Ther. 63, 694–701.PubMedGoogle Scholar

REFERENCES

  1. Fukui, N., et al. (2003). J. Bone Joint Surg. (in press).Google Scholar
  2. Van de Loo, A. A. J., et al. (1994). Agents Actions 41, 2000–2008.Google Scholar
  3. Van Beuningen, H. M., et al. (1991). Arthritis Rheum. 34, 606–615.PubMedGoogle Scholar

REFERENCES

  1. Burtscher, M., et al. (1995). Lancet 346, 254.Google Scholar
  2. Burtscher, M. (1999). Wien Klin. Wochenschr. 111, 830.PubMedGoogle Scholar
  3. Broome, J. R., et al. (1994). Aviat. Space Environ. Med. 65, 19.PubMedGoogle Scholar

REFERENCES

  1. Albano, S. A., et al. (2001). Semin. Arthr. Rheum. 31, 146–159.Google Scholar
  2. Butt, W. C., et al. (1974). Clin. Chem. 20, 1344–1348.PubMedGoogle Scholar

REFERENCES

  1. Muscara, M. N. and Wallace, J. L. (1999). Am. J. Physiol. 276, G1313.PubMedGoogle Scholar
  2. Wallace, J. L., et al. (2000). Gastroenterology 119, 706.PubMedGoogle Scholar

REFERENCES

  1. Wallace, J. L., et al. (2000). Gastroenterology 119, 706.PubMedGoogle Scholar
  2. Muscara, M. N. and Wallace, J. L. (1999). Am. J. Physiol. 276, G1313.PubMedGoogle Scholar

REFERENCES

  1. Atkinson, D. E. (1968). The energy charge of the adenylate pool as regulatory parameter. Interaction with feedback modifiers, Biochemistry 7, 4030–4034.PubMedGoogle Scholar
  2. Davenport, H. V. (1970). Backdiffusion of acid through the gastric mucosa and its physiological consequences, Dig. Dis. Sci. 21, 141–143.Google Scholar
  3. Mózsik, Gy., Figler, M., Nagy, L., et al. (1981). Gastric and small intestinal energy metabolism in mucosal damage, Adv. Physiol. Sci. 29, 213–276.Google Scholar
  4. Mózsik, Gy., Morón, F. and Jávor, T. (1982). Cellular mechanisms of the development of gastric mucosal damage and of gastrocytoprotection induced by prostacyclin in rats. A pharmacological study, Prostaglandins Leukotrienes Med. 9, 71–84.Google Scholar

Copyright information

© VSP 2003 2003

Personalised recommendations